Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single Ascending Dose Study of OTL-038 for Intra-operative Imaging in Folate Receptor Alpha Positive Ovarian, Renal Cell, and Endometrial Cancer
2014-002352-12Phase 2Completed
- Sponsor
- On Target Laboratories
- Start
- Jun 2014
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pafolacianine in ovarian cancer, renal cell carcinoma (RCC) and endometrial cancer (EC), sponsored by On Target Laboratories. Primary endpoints: Safety and tolerability of single IV doses of OTL-038 and Ex-vivo imaging efficacy across different imaging systems. Started Jun 2014; status: completed.
02
Drugs
pafolacianine
03
Conditions
ovarian cancerrenal cell carcinoma (RCC)endometrial cancer (EC)
Beyond the preview
Go deeper on 2014-002352-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002352-12.